Last updated: August 6, 2026
Inderal LA is the extended-release formulation of propranolol hydrochloride, a mature beta-blocker marketed in a largely genericized U.S. category. Its commercial value comes from recurring prescriptions, physician familiarity, and differentiated once-daily delivery rather than from patent exclusivity. Generic competition, low therapeutic switching costs, and limited public product-level disclosure constrain pricing and revenue growth.
What is Inderal LA and how is it used?
Inderal LA contains propranolol hydrochloride in an extended-release capsule designed for once-daily administration. The product is associated with several cardiovascular and neurologic indications, including hypertension, angina pectoris, migraine prophylaxis, hypertrophic subaortic stenosis, and use as an adjunct in pheochromocytoma management, subject to the product labeling and clinical context.[1]
| Attribute |
Inderal LA |
| Active ingredient |
Propranolol hydrochloride |
| Dosage form |
Extended-release capsule |
| Typical strengths |
60 mg, 80 mg, 120 mg, 160 mg |
| Therapeutic class |
Nonselective beta-adrenergic blocker |
| FDA application |
NDA 018343 |
| Administration |
Once daily |
| Primary market |
U.S. branded and generic prescription market |
| Current commercial position |
Mature branded product competing with generic propranolol ER |
Inderal LA differs from immediate-release propranolol tablets primarily through its delivery profile. The extended-release formulation reduces dosing frequency but does not create a new active pharmaceutical ingredient or a new therapeutic class.
When did Inderal LA lose exclusivity?
Inderal LA lost meaningful market exclusivity decades ago. Propranolol was first approved in the United States in the 1960s, and extended-release propranolol products have been exposed to generic competition for many years.[2]
The product’s current commercial protection is therefore based on brand recognition, formulation familiarity, supply reliability, physician prescribing habits, and channel positioning. These factors are weaker than composition-of-matter or active formulation patents because generic manufacturers can compete on price once FDA approval is available.
What is the Orange Book status of Inderal LA?
Inderal LA is associated with an approved FDA new drug application, but its commercial position does not depend on a current, high-value patent barrier. The FDA Orange Book records patents and regulatory exclusivities submitted for listed products, but historical approval does not imply continuing patent protection.[3]
The principal regulatory situation is:
| Regulatory factor |
Commercial effect |
| Original NDA approval |
Established safety and efficacy record |
| Long elapsed time since approval |
No meaningful new-drug exclusivity |
| Generic propranolol ER approvals |
Direct price competition |
| Orange Book patent protection |
No known commercially significant remaining exclusivity barrier |
| Pediatric exclusivity |
Not a current primary driver |
| Orphan exclusivity |
Not applicable to the core product |
A definitive patent-by-patent Orange Book conclusion requires a current FDA listing review because listings and product-status records can change. The economic conclusion is clear: Inderal LA is a post-exclusivity product.
How many patents cover Inderal LA?
The historical patent estate for propranolol and its extended-release delivery systems has largely expired. The active ingredient patent estate is no longer a barrier to generic entry. Any remaining protection would more likely involve formulation, manufacturing, or product-specific intellectual property rather than the propranolol molecule itself.
What formulations are protected by Inderal LA patents?
The commercial distinction is the extended-release capsule formulation. Potential historical formulation claims could cover release characteristics, excipient combinations, capsule technology, or manufacturing processes. Those claims have limited current value if they have expired or if alternative formulations can meet FDA requirements without infringement.
Generic propranolol ER products can compete through:
- Equivalent extended-release performance.
- Alternative inactive ingredients.
- Different capsule manufacturing methods.
- Abbreviated New Drug Application approval.
- Lower wholesale acquisition cost.
- Pharmacy substitution and formulary access.
The formulation does not create a durable barrier comparable to a biologic manufacturing platform or a recently patented long-acting delivery system.
How does Inderal LA compare with generic propranolol ER?
Generic propranolol ER is the main competitive threat. The products target the same prescription demand and are generally substitutable when the dosage form and strength are appropriate.
| Dimension |
Inderal LA |
Generic propranolol ER |
| Regulatory basis |
Original NDA |
ANDA |
| Brand status |
Branded legacy product |
Generic |
| Price position |
Premium or branded price |
Lower price |
| Clinical familiarity |
High |
High |
| Pharmacy substitution |
Usually lower than generic products |
Strong |
| Prescriber dependence |
May persist for stable patients |
Limited for new starts |
| Patent dependence |
Minimal |
Not dependent on brand patents |
| Growth potential |
Low |
Volume-led, margin-sensitive |
The product can retain a niche among patients stabilized on the branded capsule, physicians who prefer the original product, and payers with limited substitution pressure. That niche is vulnerable when formularies impose higher patient cost sharing or when pharmacies automatically substitute generic propranolol ER.
Which companies compete with Inderal LA?
Competition comes from generic manufacturers and from alternative beta-blockers rather than from another dominant branded propranolol franchise.
Direct generic competitors
Direct competition includes manufacturers of propranolol hydrochloride extended-release capsules approved through the ANDA pathway. The competitive field can change as approvals, marketing status, manufacturing capacity, and supply decisions change.
Generic competition typically affects Inderal LA through:
- Lower acquisition cost for pharmacies and wholesalers.
- Higher substitution rates.
- Reduced prescriber attention to brand-specific prescribing.
- Contracting pressure from managed-care organizations.
- Greater vulnerability to shortages or discontinuations at individual suppliers.
Therapeutic alternatives
Inderal LA also competes indirectly with other beta-blockers and cardiovascular therapies, including metoprolol extended-release, atenolol, nadolol, carvedilol, and other agents selected according to indication and patient characteristics.
The competitive threat varies by use:
- Hypertension has many low-cost alternatives.
- Migraine prophylaxis has several oral preventive therapies.
- Angina treatment has multiple pharmacologic options.
- Certain patients may remain on propranolol because of clinical history, tolerability, or physician preference.
- Nonselective beta-blockade is clinically relevant in some indications but can be unsuitable for patients with asthma, bradycardia, or selected metabolic risks.
What is the financial trajectory of Inderal LA?
Inderal LA is best characterized as a mature, stable-to-declining branded-generic asset rather than a growth product. Public-company filings generally disclose total company revenue and selected product or portfolio information, but they do not consistently provide an audited, standalone revenue line for Inderal LA.[4]
The likely financial trajectory is:
| Period |
Market condition |
Expected financial effect |
| Early commercialization |
Branded, protected product |
High pricing power and strong margins |
| Post-generic entry |
Direct generic competition |
Rapid price and share erosion |
| Mature branded phase |
Stable residual prescriptions |
Lower but recurring revenue |
| Current market |
Genericized category |
Limited volume growth and continuing price pressure |
The principal financial value lies in cash generation from an established prescription base. Revenue is exposed to:
- Generic substitution.
- Reimbursement changes.
- Wholesale and pharmacy purchasing decisions.
- Product availability.
- Manufacturing costs.
- Contracting and rebate requirements.
- Prescriber migration to alternative beta-blockers.
Because propranolol ER is an old product, meaningful revenue expansion would require price increases, broader distribution, supply disruption among competitors, or portfolio-level cross-selling. Unit growth from increased diagnosis or expanded indications is unlikely to materially change the product’s trajectory.
What is the revenue exposure for the product owner?
The product owner’s exposure is difficult to quantify because Inderal LA is generally reported within a broader branded or specialty pharmaceutical portfolio. Company filings do not establish a reliable, recurring standalone revenue series for the product.[4]
The economic exposure is likely concentrated in gross-to-net dynamics rather than in large research and development spending. Key deductions may include:
- Wholesaler and distributor discounts.
- Managed-care rebates.
- Returns and allowances.
- Chargebacks.
- Commercial promotion.
- Manufacturing and quality-control costs.
For a mature product, operating margins can remain attractive if manufacturing costs are low and demand is predictable. That margin profile can deteriorate quickly if the product loses formulary access, experiences supply interruptions, or requires costly remediation.
What manufacturing and intellectual-property barriers remain?
Manufacturing is a more relevant barrier than patent exclusivity. Extended-release propranolol capsules require control of release characteristics, content uniformity, dissolution, stability, and capsule performance. A manufacturer must also maintain FDA-compliant facilities, validated processes, quality systems, and dependable active pharmaceutical ingredient supply.
These requirements create operational barriers but do not prevent competition. Generic manufacturers with established oral-solid-dose capabilities can usually address them through standard development and regulatory pathways.
Manufacturing risk factors
| Risk |
Potential impact |
| API supply disruption |
Stock-outs and lost prescriptions |
| Dissolution variability |
FDA quality concerns or batch failures |
| Contract manufacturing dependence |
Margin and continuity risk |
| Low market price |
Reduced supplier participation |
| Small market size |
Limited incentive for redundant capacity |
| Regulatory inspection findings |
Delays, recalls, or supply interruption |
The product’s manufacturing economics can produce a paradox: low prices benefit payers but may reduce the number of manufacturers willing to maintain capacity. That can increase shortage risk without restoring durable pricing power to the brand.
Are there Paragraph IV challenges to Inderal LA?
Paragraph IV litigation is not the main current risk to Inderal LA. Paragraph IV certifications typically matter when a generic applicant seeks approval before expiration of an Orange Book-listed patent. For an old propranolol ER product with no apparent commercially meaningful remaining patent barrier, the competitive process is more likely to involve ordinary generic approval, launch timing, and market-share capture than a new patent dispute.
Potential litigation could still arise from:
- A newly listed formulation patent.
- Patent-use-code disputes.
- ANDA infringement claims.
- Manufacturing or trade-secret allegations.
- Product liability or quality disputes.
No current, material Paragraph IV dispute is identified here as a central driver of Inderal LA’s market outlook.
What patent litigation affects Inderal LA?
There is no established current patent litigation thesis comparable to the disputes surrounding recently approved specialty drugs, long-acting injectables, or biologics. The principal legal risk is ordinary post-exclusivity competition.
A litigation review should distinguish among:
- Historical patent cases involving propranolol or related formulations.
- ANDA litigation involving a specific generic applicant.
- Current commercial disputes involving the marketed product.
- Patent challenges that no longer affect launch timing because the relevant patent has expired.
For investment analysis, old litigation has limited relevance unless it produced an enforceable settlement, restricted a manufacturing process, or created a continuing supply obligation.
Are there licensing deals for Inderal LA?
Inderal LA has historically moved through legacy pharmaceutical portfolios and licensing or acquisition arrangements rather than through an active innovation partnership model. The product’s current value is more consistent with a commercialized mature-brand transaction than with a royalty-bearing discovery collaboration.
Licensing economics for such a product generally depend on:
- Net sales after rebates and discounts.
- Minimum purchase obligations.
- Territory.
- Manufacturing responsibility.
- Regulatory responsibility.
- Product liability allocation.
- Rights to approve price changes.
- Termination rights for supply failure or quality events.
Public disclosures may identify the product within a portfolio transaction without reporting product-specific royalty rates or profitability. Those terms should not be inferred from the brand’s historical launch price.
What FDA regulatory risks apply to Inderal LA?
FDA risk is primarily operational and labeling-related. The product label warns about bradycardia, hypotension, bronchospasm, heart failure, masking of hypoglycemia, and risks associated with abrupt discontinuation.[1]
Regulatory and commercial risks include:
- Manufacturing deviations.
- Stability failures.
- Dissolution or release-profile problems.
- Labeling noncompliance.
- Drug shortages.
- Recall activity.
- Pharmacovigilance obligations.
- Failure to maintain current product listings.
Because propranolol is widely used and clinically familiar, major regulatory upside is limited. Regulatory intervention would be more likely to reduce sales than expand them.
What generic launch scenarios exist for Inderal LA?
The market is already in the genericized phase, so “generic launch risk” means additional supplier entry, share shifts, or aggressive pricing rather than the first generic launch.
Base case
Generic propranolol ER retains the majority of volume. Inderal LA preserves a smaller branded share supported by stable patients and prescriber familiarity. Revenue declines gradually through price pressure and substitution.
Downside case
A payer or pharmacy channel increases mandatory substitution, or a branded supplier experiences a supply interruption. Inderal LA loses volume rapidly, while generic alternatives capture prescriptions.
Supply-driven upside case
A manufacturing problem affects one or more generic suppliers. The brand may recover temporary volume or pricing power if it remains reliably available. This upside is usually episodic and does not establish long-term growth.
Portfolio monetization case
The owner continues to harvest cash flow, reduces promotional spending, and markets the product as part of a broader legacy portfolio. Value depends on margin preservation rather than prescription expansion.
How strong is the Inderal LA patent estate?
The patent estate is weak as a current source of exclusivity. The product’s strength is commercial and operational, not patent-based.
| Patent-estate factor |
Assessment |
| Active ingredient protection |
Expired |
| New-drug exclusivity |
Expired |
| Formulation exclusivity |
Historical and likely expired or commercially limited |
| Method-of-use protection |
Limited practical value |
| Manufacturing patents |
Potentially relevant only if unexpired and product-specific |
| Orange Book leverage |
Low |
| Generic entry barrier |
Low |
| Litigation leverage |
Low |
Inderal LA should be valued as a mature branded generic with recurring demand, not as a protected pharmaceutical asset.
How does Inderal LA compare with InnoPran XL?
Inderal LA and InnoPran XL are both extended-release propranolol products, but they have different commercial histories and market positioning. InnoPran XL was developed as a branded extended-release propranolol product with a different formulation and dosing concept. Inderal LA has the stronger legacy brand association with propranolol, while both products face generic and therapeutic competition.
| Factor |
Inderal LA |
InnoPran XL |
| Active ingredient |
Propranolol hydrochloride |
Propranolol hydrochloride |
| Dosage concept |
Extended release |
Extended release |
| Commercial profile |
Legacy branded product |
Specialty branded formulation |
| Competitive pressure |
Generic propranolol ER |
Generic and alternative beta-blockers |
| Patent value today |
Limited |
Dependent on any surviving product-specific rights |
| Main value driver |
Brand continuity and supply |
Formulation positioning and niche demand |
Neither product has the growth profile of a recently launched specialty medicine.
Key Takeaways
- Inderal LA is a mature extended-release propranolol product with no meaningful remaining molecule-level exclusivity.
- Generic propranolol ER is the primary direct competitor.
- Revenue is likely recurring but flat to declining, with product-level sales not consistently disclosed in public filings.
- Commercial value depends on brand retention, supply reliability, manufacturing cost, and payer positioning.
- Patent and Paragraph IV risk are low relative to operational, pricing, and substitution risks.
- Formulation know-how can support quality and supply differentiation but does not create a strong barrier to generic competition.
- The product is more suitable for cash-flow harvesting or portfolio management than for growth-oriented pharmaceutical investment.
- The principal upside is temporary supply-driven share recovery; the principal downside is accelerated generic substitution.
FAQs
Is Inderal LA still available in the United States?
Inderal LA has been marketed as a propranolol hydrochloride extended-release product, but availability can vary by supplier, strength, pharmacy channel, and product-listing status. Generic propranolol ER is more broadly relevant to current market access.
Does Inderal LA have a patent-protected extended-release formulation?
Any historical formulation protection is unlikely to provide a current broad barrier to generic entry. The market is primarily governed by FDA approval, manufacturing capability, and commercial contracting.
Can pharmacies substitute generic propranolol ER for Inderal LA?
Substitution depends on FDA equivalence, state pharmacy law, prescription instructions, payer policy, dosage strength, and the pharmacist’s assessment. Extended-release products should not be treated as interchangeable solely because they contain propranolol.
Is Inderal LA a growth product for its owner?
No. It is more accurately classified as a mature branded-generic asset with modest recurring demand and limited structural growth potential.
Does Inderal LA face biosimilar competition?
No. Inderal LA is a small-molecule drug, not a biologic. Its relevant competition comes from generic drugs approved under the ANDA pathway, not biosimilars.
References
- DailyMed. (n.d.). Inderal LA: Propranolol hydrochloride extended-release capsules prescribing information. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs, Inderal LA, NDA 018343.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- ANI Pharmaceuticals, Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission.
